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Abstract: Epigenetic alterations have been reported in colorectal neoplasia which can either complement
or in some cases be predisposed to genetic alterations such as K-ras mutations. We examined the promoter
methylation status of the CDKN2A and O6-methylguanine-DNA methyltransferase (MGMT) genes, af-
ter sodium bisulfite conversion and DNA amplification with methylation specific PCR. Moreover, we
searched for G to A transitions in codons 12 and 13 of the K-ras oncogene in normal colorectal mucosae,
aberrant crypt foci (ACF, early premalignant lesions) and carcinomas. CDKN2A hypermethylation was
an infrequent event in ACF (2 of 26, 7.7%). On the contrary, MGMT hypermethylation was found in
the normal mucosae (3 of the 12 samples, 25%), in 14 of the 26 ACF (53.8%) and in 7 of the 9 (77.8%)
carcinomas examined. K-ras mutations were evident in 6 ACF (23%) and in 3 carcinomas (33.3%), mostly
associated with MGMT promoter hypermethylation. These findings strongly support the hypothesis that
epigenetic mechanisms play an important role in the early steps of colorectal carcinogenesis.
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Abstract. Epigenetic alterations have been reported in colo-
rectal neoplasia which can either complement or in some
cases be predisposed to genetic alterations such as K-ras
mutations. We examined the promoter methylation status of
the CDKN2A and O6-methylguanine-DNA methyltransferase
(MGMT) genes, after sodium bisulfite conversion and DNA
amplification with methylation specific PCR. Moreover, we
searched for G to A transitions in codons 12 and 13 of the
K-ras oncogene in normal colorectal mucosae, aberrant crypt
foci (ACF, early premalignant lesions) and carcinomas.
CDKN2A hypermethylation was an infrequent event in ACF
(2 of 26, 7.7%). On the contrary, MGMT hypermethylation
was found in the normal mucosae (3 of the 12 samples,
25%), in 14 of the 26 ACF (53.8%) and in 7 of the 9 (77.8%)
carcinomas examined. K-ras mutations were evident in 6
ACF (23%) and in 3 carcinomas (33.3%), mostly associated
with MGMT promoter hypermethylation. These findings
strongly support the hypothesis that epigenetic mechanisms
play an important role in the early steps of colorectal carcino-
genesis.
Introduction
Aberrant crypt foci (ACF) are the earliest morphological step
in the development of colorectal cancer (1,2). A large body
of evidence has been produced in support of this contention,
including the presence of some genetic alterations in ACF
occurring at the later stages of colorectal carcinogenesis (3),
even in hereditary cases (4). Most of these alterations are
mutations or chromosomal deletions affecting tumor
suppressor genes or genes controlling DNA mismatch-
repair, causing the loss of function of these genes. Epigenetic
mechanisms have also been reported in colorectal carcino-
genesis. In particular, transcriptional silencing through the
hypermethylation of the CpG islands in the promoter regions
of several genes has been demonstrated in colorectal cancer
(5), adenomas (6), and even in human ACF (7,8). Furthermore,
the hypermethylation of the CpG islands in the promoter
region of hMLH1 underlies most sporadic colorectal cancers
with microsatellite instability, and it has also been found in
normal mucosae as an age-related phenomenon (9). K-ras
activating mutations, mainly at codon 12, occur frequently in
colorectal cancer and in other tumors, and in some instances,
they correlate with the silencing of O6-methylguanine-DNA
methyltransferase (MGMT) through promoter hypermethyl-
ation (10,11). K-ras mutations have been found also at the
stage of ACF (12). It is noteworthy that the transgenic over-
expression of human MGMT inhibits the development of
azoxymethane-induced ACF and the occurrence of specific
K-ras mutations in mice (13), suggesting an important role
for this pathway in colorectal tumorigenesis. CDKN2A (p16)
is a tumor suppressor gene, whose inactivation leads to the
deregulation of cell proliferation and to genomic instability.
In some cases it has been shown to be silenced by promoter
hypermethylation even at the early stages of tumor progression
(14). Thus, we evaluated whether, and to what extent, p16
and MGMT were silenced by promoter hypermethylation in
human ACF using a real-time PCR technique, and whether
such events had functional consequences on the K-ras onco-
gene.
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Materials and methods
Sample collection. We collected specimens of colorectal
mucosa from 12 patients after surgery for colorectal cancer
or benign diseases of the large bowel (Table I). Nine patients
had colorectal carcinoma at the time of surgery. The remaining
three patients had no cancer in the resected specimen. Two of
them (nos. 7 and 8) however, had an adenoma, one of whose
had been removed 3 months prior to surgery, and the other
one at the time of surgery. Informed consent for the use of
the colonic samples was obtained from the patients. The
protocol of the study was reviewed by the local ethics
committee. The mucosal surface was examined under a
dissecting microscope after staining with methylene-blue, as
previously described (15). When ACF were identified, the
number of crypts and the prevalent shape of the crypt luminal
openings in ACF were recorded, and then dissected, avoiding
as many normal surrounding crypts as possible, and stored at
-80˚C until the analysis. The number of crypts in ACF has
been referred to as crypt multiplicity, which is considered an
estimate of the size of ACF. The prevalent shape of the crypt
openings in ACF was divided into 3 main features: round (R),
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Table I. Features of patients and ACF examined.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patient Sex/age Disease ACF no. Sitea ACF Shape of crypt
no. multiplicityb openings in ACFc
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 F 78 Cancer 1 Left colon 150 S
2 M 75 Sigmoiditis 2 Left colon 250 S
3 F 79 Cancer 3 Left colon 150 R
4 40 R
5 130 R




5 F 48 Cancer 10 Rectum 10 S
6 M 83 Cancer 11 Right colon 50 S




8 M 69 Adenoma 16 Right colon 70 R
9 M 55 Cancer 17 Left colon 70 R
18 80 R
10 M 45 Cancer 19 Rectum 100 E





12 M 94 Cancer 25 Right colon 100 E
26 400 R
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aThe site of colorectal mucosa examined in search for ACF. Right colon = cecum, ascending colon, hepatic flexure, transverse colon, splenic
flexure; left colon = descending colon and sigmoid colon; rectum = rectosigmoid junction and rectum. bNumber of crypts per ACF. cS,
serrated; R, round; E, elongated (15).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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serrated (S), and elongated (E). These 3 shapes are strictly
related to the histology of ACF (15). In particular, the round
or serrated luminal openings identify nondysplastic ACF,
whereas the elongated ones define dysplastic ACF. For each
patient at least 1 sample of normal mucosa was also taken. A
total of 26 ACF were available for the analysis, as shown in
Table I. For all the patients with cancer, carcinoma samples
were also taken at surgery. Also available, were adenoma and
hyperplastic polyp samples which were taken from two
patients and one patient, respectively.
Cell lines. The colon cancer cell lines, CO115, GP5-D,
HCT116 and LS174T, were kindly provided by The Zurich
Cancer Network.
Nucleic acid isolation. Genomic DNA was extracted with
the QUIamp DNA mini kit (Qiagen) according to the manu-
facturer's instructions.
Sodium bisulfite conversion. Sodium bisulfite conversion of
the genomic DNA was performed as previously described
(16), with minor modifications. Briefly, DNA (2 μg) was
diluted in 50 μl distilled water and then denaturated by a final
concentration of 0.3 M NaOH for 20 min at 37˚C. Thirty
microliters 10 mM hydroquinone (Sigma) and 520 μl 3.46M
sodium bisulfite (Sigma) at pH 5.0 were then added, and the
samples were incubated at 50˚C for 16-18 h. Subsequently,
the DNA was purified using the Wizard DNA Clean-Up
system (Promega), following the manufacturer's protocol.
The DNA was then desulfonated with 0.3 M NaOH for 20 min
at 37˚C, neutralized with 18 μl 10 M ammonium acetate, preci-
pitated with ethanol and finally resuspended in 20 μl water.
Methylation-specific PCR (MSP). The modified DNA was
subjected to methylation-specific PCR (MSP) with allele-
specific primers complementary to the modified or
unmodified sequences of the gene promoters studied. For
CDKN2A (p16) the following primers were designed: p16
methylation-specific, 5' GTTAACGTTGGTTTTGGCGA 3'
(sense) and 5' ACGCTATAAACGAATACTCGAA 3' (anti-
sense); and p16 nonmethylation-specific, 5' TGTTAATGTT
GGTTTTGGTGAG 3'(sense) and 5' CACAATATCTTT
CCAAACAAAAAAACA 3' (antisense) (amplicon location
from -323 to -167 for the methylated reaction and from -324
to -143 for the unmethylated from the ATG transcription start
codon; GenBank accession no. X94154). For MGMT promoter
analysis the following primers were used: the methylation-
specific 5' AGGCGTCGTTCGGTTTGTATCG 3' (sense)
and 5' CGCCGAACCTAAAACAATCTACG 3' (antisense);
and the unmethylation-specific 5' GGTGGAAGTTGG
GAAGGTGTTG 3' (sense) and 5' CAACACATACCCA
ATACAACAACACCA 3' (antisense) with products located
from 703 to 831 for the methylated reaction and from 689 to
853 for the unmethylated in the MGMT promoter sequence
(GenBank accession no. X61657).
Real-time PCR was performed by the Roche LightCycler
system using the QuantiTect SYBR-Green kit (Qiagen)
according to the manufacturer's instructions (0.5 μM of each
primer and 2 μl modified DNA in a 20 μl final reaction
volume). Real-time cycler conditions were as follows: after
an initial activation step (95˚C for 15 min), 55 cycles (94˚C
for 15 sec; 60˚C for the methylated reactions and 58˚C for
the unmethylated, for 20 sec; 72˚C for 10 sec) followed by a
melting curve analysis step. The specificity of the reactions
was confirmed by using positive controls for the methylated
reactions for both the gene promoters examined; we used the
fully-methylated DNA in the MGMT promoter from the
CO115 colorectal cancer cell line and the hemimethylated
DNA in the CDKN2A promoter from the HCT116 colorectal
cancer cell line (17). DNA from normal lymphocytes was
used as a negative control.
MGMT gene promoter bisulfite sequencing. Bisulfite
sequencing was performed in several ACF and in the CO115
and GP5D colorectal cancer cell lines. A region from 666 to
1127 in the MGMT promoter sequence (GenBank accession
no. X61657), which contains 63 CpG sites, was amplified
from the modified DNA by PCR using HotStarTaqDNA
polymerase (Qiagen) with the following primers: GGGAA
TTCGTAAATTAAGGTATAGAGTTTTAGG (sense) and
TGTGGATCCCAAACACTCACCAAATC (antisense). The
PCR conditions were as follows: one cycle of denaturing at
95˚C for 15 min, followed by 35 cycles at 94˚C for 30 sec,
51˚C for 30 sec, and 72˚C for 1 min before a final extension
at 72˚C for 10 min. The PCR products were cloned into the
pGEM-T7 Vector (Promega) and the clones were sequenced
by the Applied Biosystems PRISM dye terminator cycle
sequencing method.
Detection of G to A transitions in K-ras codons 12 and 13.
Mutant allele-specific amplification (MASA) was performed
by real-time PCR in 20 μl reaction volumes using the
QuantiTect SYBR-Green kit (Qiagen), 50 ng template and
0.5 μM of each allele-specific primer, whose sequences were
previously described (11). The PCR conditions were the
same as those used for the methylation analysis except for
the annealing temperatures (62˚C for the detection of G to A
transitions in the first base of codon 12, 63˚C for the second
base of codon 12 and the first base of codon 13, and 64˚C for
the second base in codon 13) for a total of 50 cycles of
amplification. The positive controls for the transitions in the
second base of codons 12 and 13 were DNA from the
LS174T and HCT116 colorectal cancer cell lines,
respectively. DNA from normal lymphocytes was used as a
negative control.
Results
In order to be able to detect even low levels of genetic and
epigenetic alterations in normal mucosae and in ACF, we
chose an allele-specific amplification approach, which by the
use of the real-time PCR technology, could guarantee high
sensitivity and specificity (Fig. 1). Moreover, the positivity
of a sample was validated by melting curve analyses including
positive controls and the right lengths of the amplicons were
examined by agarose gel electrophoresis (Fig. 2). In addition,
MGMT promoter bisulfite sequencing was performed in
several ACF and in the control colorectal cell lines (Fig. 3).
The results of the methylation analysis of CDKN2A (p16)
and the MGMT gene promoters and the detection of G to A
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transitions in codons 12 and 13 of the K-ras oncogene are
shown in Table II. CDKN2A hypermethylation was observed
in only 2 ACF (7.7%), in 3 of the 9 carcinomas (33.3%), and
in none of the normal mucosa and polyp samples. On the
contrary, the MGMT promoter was methylated in more than
half of the ACF analyzed (14 of 26, 53.8%) and in 3 of the 7
patients with ACF methylated in MGMT this epigenetic
change was also present in the normal mucosae. As far as K-
ras mutational analysis is concerned, G to A transitions were
found in 6 ACF (23%): one in the first base of codon 12, 4 in
the second base of codon 12, and one in the second base of
codon 13. Five of these ACF also showed MGMT promoter
hypermethylation (Table II). No mutation was found in the
first base of codon 13 in ACF. MGMT promoter hyper-
methylation was also found in 7 of the 9 carcinomas
examined (77.8%), and in two of them a G to A transition in
the second base of codon 12 was also present. One carcinoma
(patient no. 12) showed a K-ras mutation but no MGMT
promoter methylation. Finally, the two adenomas examined
showed a K-ras mutation in the second base of codon 13,
but only one of them had concomitant MGMT promoter
hypermethylation.
Discussion
The data presented are consistent with MGMT promoter
hypermethylation being an early event in colorectal carcino-
genesis. MGMT protects cells from the mutagenic and
cytotoxic effects of environmental alkylating carcinogens
by transferring the mutagenic methyl group from the O6-
position of guanine to a cysteine residue at its active site
(18). If this alkyl adduct cannot be removed as a consequence
of MGMT inactivity, O6-methylguanine will mispair with
thymine during replication, resulting in a G to A transition.
Consequently, we searched for mutations of this kind in
codons 12 and 13 of the K-ras oncogene. In our study, the
specificity of MGMT promoter hypermethylation detection
was obtained using allele-specific primers in a region
previously shown to be heavily methylated and associated
with local heterochromatinization of the transcription start
site in the MGMT-silenced cells (19). The percentage of ACF
with MGMT promoter hypermethylation was much higher
(53.8%) than that reported by Chan et al (12%) who first
described the changes in methylation in the promoter region
of some genes in ACF (7), while similar percentages were
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Figure 1. Amplification profile (on the left) and melting curve analysis (on the right) of allele-specific amplifications performed by real-time PCR. The
positivity of the samples and controls is shown by the increasing of the fluorescence signals, while the negative samples and controls remain at the baseline.
(Panel A) MGMT promoter amplification with methylated allele-specific primers. (Panel B) CDKN2A (p16) promoter methylated products. (Panel C) MASA
of samples with G to A transitions in codon 12 (second base) of the K-ras oncogene.
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found for CDKN2A (p16) promoter hypermethylation (7.7%
vs 4%). This discrepancy could be due to the older median
age of the patients in our study (68.8 vs 54.5 years), and also
to the absence of patients with familial adenomatous polyposis,
who were included in Chan's study (12). In the present study,
the mean age of the patients with hypermethylated MGMT in
the normal mucosa and/or in at least one ACF was ten years
older than that of the patients with no MGMT methylation.
Thus, MGMT promoter hypermethylation is an age-related
phenomenon, as it has also been shown for the hMLH1
promoter (9), and for other gene promoters (20), even in
normal mucosae. A recent study supports this evidence
showing the correlation of the MGMT methylation level with
age in the normal colonic mucosae of patients with cancers
silenced in this gene (21). The authors of this study suggested
a field effect molecularly defined by the epigenetic inacti-
vation of MGMT from which some sporadic colorectal
cancers may arise. We show that ACF may have not only
molecular but also morphological features to satisfy the
definition of a field effect in carcinogenesis (22). In our study
MGMT promoter hypermethylation was not dependent on
ACF size (Table I, crypt multiplicity) or histology (Table I,
shape of crypt openings in ACF) (15). In fact, even a 10-crypt
ACF (Table I, ACF no. 10), and a nondysplastic ACF (serrated
and round luminal openings) were MGMT-hypermethylated.
MGMT hypermethylation was also demonstrated in ACF
from patients with benign diseases of the large intestine
(Table II, patients no. 2, 7 and 8).
We propose a possible ‘field effect’ due to this epigenetic
alteration, which could be found in the same patient not only
in cancer and in ACF but, in some cases, even in the normal
colonic mucosa. In this context, MGMT-silenced cells are
predisposed, in the presence of environmental alkylating
carcinogens, to acquire somatic mutations (G to A transitions)
that can affect not only K-ras but also p53 (23), and potentially
many other genes whose gain or loss of function may be
responsible for the transition from normal mucosa, through
ACF, to adenoma and carcinoma. In this study, K-ras muta-
tions were found almost exclusively in the lesions with MGMT
promoter hypermethylation. However, MGMT silencing was
not a condition per se which invariably led to K-ras mutations.
In fact, only 5 of the 13 (38.4%) MGMT-hypermethylated
ACF and 2 of the 7 (28.6%) MGMT-hypermethylated
carcinomas showed this alteration. The frequency of K-ras
mutations found in ACF in the present study was lower than
those reported in other investigations, however, considering
only G to A transitions, it is in the range of previous studies
in humans (12,24-26). Our data support the association
between MGMT promoter hypermethylation and G to A
transitions in K-ras in colorectal tumorigenesis (10). However,
this association could be a weak one, as recently reported by
Halford et al (27).
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Figure 2. (Panel A) Examples of MGMT promoter methylation analysis in
ACF and colorectal cancers (CRC). The presence of a visible PCR product
in the lanes U, indicates the presence of unmethylated alleles in the sample,
while a product in lanes M indicates the presence of MGMT promoter
methylated alleles. The colorectal cancer cell line CO115, fully-methylated
in the MGMT promoter, was used as the positive control fo the reactions
(product only in lane M). (Panel B) CDKN2A (p16) promoter methylation
analysis. In this case the hemimethylated DNA in the CDKN2A promoter
from the HCT116 colorectal cancer cell line was used as the control (visible
PCR products in lanes U and M). (Panel C) Detection of G to A transitions
in codon 12 (second base) of the K-ras oncogene by MASA. Visible products
in lanes 3 (patient no. 4, CRC) and 6 (patient no. 3, ACF-1) indicate the
presence of the GAT mutation in these samples, as confirmed by the
amplification of the positive control in lane 10 (the LS174T colorectal cancer
cell line).
Figure 3. Bisulfite genomic sequencing of the MGMT gene promoter. Top, a
schematic depiction of the MGMT promoter with CpG dinucleotides (short
vertical lines). The methylation status of the individually cloned DNA
fragments of two colorectal cell lines and two ACF is shown. Each row
represents one sequenced allele. Each circle represents a CpG dinucleotide.
Filled circle, methylation; open circle, no methylation.
1421-1427  4/5/07  19:12  Page 1425
MENIGATTI et al:  MGMT PROMOTER METHYLATION IN COLORECTAL CARCINOGENESIS1426
Table II. CDKN2A and MGMT promoter hypermethylation.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patient Lesion CDKN2A MGMT K-ras K-ras K-ras K-ras
no. promoter promoter codon 12 codon 12 codon 13 codon 13
hypermethylation hypermethylation AGT GAT AGC GAC
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 NM - - - - - -
ACF-1 - - - - - -
K - + - - - -
2 NM - - - - - -
ACF-1 - + - - - -
3 NM - + - - - -
ACF-1 - + - + - -
ACF-2 - + - - - -
ACF-3 - + - - - -
K + + - - - -
4 NM - - - - - -
ACF-1 - - - - - -
ACF-2 - + - - - -
ACF-3 - + - - - -
ACF-4 + + - + - -
K + + - + - -
-
5 NM - + - - - -
ACF-1 - + - - - -
K - + - - - -
6 NM - - - - - -
ACF-1 - - - - - -
K - + - - - -
7 NM - + - - - -
ACF-1 - + - + - -
ACF-2 - + - - - -
ACF-3 - + - - - -
ACF-4 - + - - - -
8 NM - - - - - -
ACF-1 + + - + - -
Ad - + - - - +
9 NM - - - - - -
ACF-1 - - + - - -
ACF-2 - - - - - -
K - + - - - -
10 NM - - - - - -
ACF-1 - - - - - -
K - + - + - -
11 NM - - - - - -
ACF-1 - - - - - -
ACF-2 - - - - - -
ACF-3 - - - - - -
ACF-4 - - - - - -
ACF-5 - - - - - -
Hyper - - - - - -
K - - - - - -
12 NM - - - - - -
ACF-1 - - - - - -
ACF-2 - + - - - +
Ad - - - - - +
K + - + - - -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
The G to A transition was also examined in codon 12 (wild-type GGT), codon 13 (wild-type GGC) of K-ras in normal colorectal mucosae
(NM), ACF, adenomas (Ad), hyperplastic polyps (Hyper), and carcinomas (K) of the large bowel.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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In conclusion, the results of the present study suggest that
MGMT silencing is an early and age-related event in colo-
rectal carcinogenesis, being present even in normal colonic
mucosae. However, the mechanisms that trigger the prefer-
entially de novo methylation of some promoter genes are still
poorly understood. These epigenetic changes can lead to the
functional activation of other genes, including K-ras, thus
starting the early genetic changes necessary for cancer
development. Further studies are needed in order to elucidate
the very early alterations which underlie colonic cell trans-
formation, and in particular, not only the qualitative, but also
the quantitative assessment of the methylation status in
normal-appearing mucosae by the use of the real-time PCR
technology.
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